Goldman Sachs Upgrades Quest Diagnostics (DGX) to Neutral

Goldman Sachs upgraded Quest Diagnostics (NYSE: DGX) from Sell to Neutral with a price target of $51.

The firm said the risk/reward is balanced.

"We anticipate a flat volume outlook, which we believe is now more appropriately priced in," the analyst said. "We expect the lower growth environment will increase focus on ROIC, where DGX falls below peers, and see uncertainty around DGX's cost cutting initiatives and capital allocation."

For more ratings news on Quest Diagnostics click here and for the rating history of Quest Diagnostics click here.

Shares of Quest Diagnostics closed at $48.93 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Wells Fargo Upgrades Portland General Electric Company (POR) to Overweight
• Seaport Global Securities Upgrades Analog Devices (ADI) to Buy, 'appears to be entering the sweet part of the cycle'
• KeyBanc Upgrades Innovage Holding Corp (INNV) to Overweight